Sugi Predict

Sugi Predict / Compounds / SCHEMBL537593

SCHEMBL537593

SCHEMBL537593

C[C@](N)(CC/C=C\CNCC=N)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GGT1 P19440 1/20 0.39
▸ ARG1 P05089 1/20 0.36
▸ ARG2 P78540 1/20 0.36
▸ ACLY P53396 1/20 0.34
▸ BLM P54132 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ FYN P06241 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ APEX1 P27695 1/20 0.33
▸ ADRA1A P35348 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6475315 1.00 GGT1 (0.39) GGT1ARG1ARG2ACLYBLM
SCHEMBL2638240 1.00 GGT1 (0.39) GGT1ARG1ARG2ACLYBLM
SCHEMBL6130501 0.84 BLM (0.34) GGT1ARG1ARG2BLMKDM4E
SCHEMBL6986975 0.84 BLM (0.34) GGT1ARG1ARG2BLMKDM4E
SCHEMBL6478143 0.84 BLM (0.34) GGT1ARG1ARG2BLMKDM4E
SCHEMBL6985887 0.84 BLM (0.34) GGT1ARG1ARG2BLMKDM4E
SCHEMBL6989001 0.83 MEN1 (0.45) ARG1ARG2ACLYMEN1ALDH1A1
SCHEMBL6992300 0.83 MEN1 (0.45) ARG1ARG2ACLYMEN1ALDH1A1
SCHEMBL7137223 0.81 ACLY (0.34) ACLY
SCHEMBL6988773 0.79 ODC1 (0.42) MEN1ALDH1A1CYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4708024-B2 — — 2011-06-22 — — JP claimed
EP-1534668-A1 CRYSTALLINE SOLID FORM OF (2S-5Z)-2-AMINO-7-(ETHANIMIDOYLAMINO)-2-METHYLHEPT-5-ENOIC ACID Pharmacia Corporation (US) 2005-06-01 — — EP claimed
WO-2005025620-A2 COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS PHARMACIA CORPORATION (US) 2005-03-24 — — WO claimed
WO-2004018412-A1 CRYSTALLINE SOLID FORM OF (2S-5Z)-2-AMINO-7-(ETHANIMIDOYLAMINO)-2-METHYLHEPT-5-ENOIC ACID PHARMACIA CORPORATION (US) 2004-03-04 — — WO claimed
EP-1317421-A1 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS Pharmacia Corporation (US) 2003-06-11 — — EP claimed
WO-2002022562-A1 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS PHARMACIA CORPORATION (US) 2002-03-21 — — WO claimed
EP-4712957-A2 ISOANDROGRAPHOLIDE ANALOGS AND METHOD FOR TREATMENT USING THE SAME Enveda Therapeutics, Inc. (US) 2026-03-25 — — EP disclosed
EP-4714435-A2 SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE Vertex Pharmaceuticals Incorporated (US) 2026-03-25 — — EP disclosed
EP-4712967-A2 G-PROTEIN COUPLED RECEPTOR ANTAGONIST Enveda Therapeutics, Inc. (US) 2026-03-25 — — EP disclosed
EP-4346818-B1 SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE VERTEX PHARMA (US) 2025-12-03 — — EP disclosed
US-20250353836-A1 N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2025-11-20 — — US disclosed
EP-3820860-B1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INST INC (US) 2025-10-15 — — EP disclosed
EP-4629974-A1 NOOTKATONE FOR THE TREATMENT OF GUT OR ABDOMINAL PAIN Enveda Therapeutics, Inc. (US) 2025-10-15 — — EP disclosed
EP-1534668-A1 CRYSTALLINE SOLID FORM OF (2S-5Z)-2-AMINO-7-(ETHANIMIDOYLAMINO)-2-METHYLHEPT-5-ENOIC ACID Pharmacia Corporation (US) 2005-06-01 — — EP disclosed
WO-2005025620-A2 COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS PHARMACIA CORPORATION (US) 2005-03-24 — — WO disclosed
EP-1463495-A2 AGENTS AND METHODS FOR TREATMENT OF CANCER Pharmacia Corporation (US) 2004-10-06 — — EP disclosed
WO-2004018412-A1 CRYSTALLINE SOLID FORM OF (2S-5Z)-2-AMINO-7-(ETHANIMIDOYLAMINO)-2-METHYLHEPT-5-ENOIC ACID PHARMACIA CORPORATION (US) 2004-03-04 — — WO disclosed
EP-1317421-A1 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS Pharmacia Corporation (US) 2003-06-11 — — EP disclosed
WO-2002076395-A2 AGENTS AND METHODS FOR TREATMENT OF CANCER PHARMACIA CORPORATION (US) 2002-10-03 — — WO disclosed
WO-2002022562-A1 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS PHARMACIA CORPORATION (US) 2002-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353836-A1 N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN2B GGT1 4722/4885ARG1 4774/4885ARG2 4272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.